UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| ||||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | SEC 1473 (7-02) | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1. Title of Derivative Security (Instr. 4) |
2. Date Exercisable and Expiration Date (Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) |
4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) |
6. Nature of Indirect Beneficial Ownership (Instr. 5) |
||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Non-qualified Stock Option (Right to Buy) (1) | 02/10/2013 | 02/10/2019 | Common Stock | 496,292 | $ 15.35 | D | Â |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
HULL CARL 35 CROSBY DRIVE BEDFORD, MA 01730 |
 |  |  SVP and GM of Diagnostics |  |
/s/ Mark J. Casey, attorney-in-fact for Carl W. Hull | 08/02/2012 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | Pursuant to the Agreement and Plan of Merger by and among Gen-Probe Incorporated ("Gen-Probe"), Hologic, Inc. ("Hologic") and Gold Acquisition Corp. dated as of April 29, 2012 and filed with the Securities and Exchange Commission of Form 8-K on May 1, 2012 ("Agreement"), the option previously issued to the Reporting Person by Gen-Probe on February 10, 2012 (110,000 shares at grant price of $69.22) shall be assumed by Hologic in accordance with the Option Exchange Ratio (conversion rate 4.51174963) and shall continue to have, and be subject to, the same terms and conditions, including vesting, applicable to such option immediately prior to the effective time of the merger. |